» Articles » PMID: 3078962

Cloning and Expression of the Ret Proto-oncogene Encoding a Tyrosine Kinase with Two Potential Transmembrane Domains

Overview
Journal Oncogene
Date 1988 Nov 1
PMID 3078962
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

The nucleotide sequence of the ret proto-oncogene has been determined from cDNA clones isolated from a cDNA library of a THP-1 human monocytic leukemia cell line. Analysis of this sequence indicates that it encodes a protein which is structurally related to transmembrane receptors with a cytoplasmic tyrosine kinase domain. Unlike most growth factor receptors, it contains two hydrophobic regions which are potential transmembrane domains. Comparison of the sequence of the ret proto-oncogene with that of the ret transforming gene revealed that, in addition to the amino-terminal truncation, the last 51 carboxy-terminal amino acids of the ret proto-oncogene were replaced with 9 unrelated amino acids of the ret transforming gene. The focus forming activity of the ret cDNA, containing both amino-terminal and caboxy-terminal truncations, was approximately 13-fold higher than that of cDNA containing only the amino-terminal truncation. This suggests a possible role for the carboxy-terminal sequence in activation of transforming potential of the ret proto-oncogene. When transcription of the ret proto-oncogene was examined in a variety of mouse tissues, we detected its transcription in normal mouse spinal cord and lymphadenopathy of C3H/HeJ-gld/gld and MRL/Mp-lpr/lpr mice.

Citing Articles

Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics.

Benfatto S, Sill M, Jones D, Pfister S, Sahm F, von Deimling A Nat Commun. 2025; 16(1):1787.

PMID: 39979307 PMC: 11842776. DOI: 10.1038/s41467-025-57078-0.


Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review.

Voinea I, Petrova E, Dumitru N, Cocolos A, Ioachim D, Goldstein A J Clin Med. 2024; 13(23).

PMID: 39685621 PMC: 11641973. DOI: 10.3390/jcm13237161.


Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.

Zhang Y, Zheng W, Zhou S, Gu J, Yu Q, Zhu Y Cell Commun Signal. 2024; 22(1):460.

PMID: 39342195 PMC: 11439284. DOI: 10.1186/s12964-024-01837-x.


Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".

Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Pellizzari G Cancers (Basel). 2024; 16(16).

PMID: 39199650 PMC: 11352804. DOI: 10.3390/cancers16162877.


Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.

Acharya B, Saha D, Garcia Garcia N, Armstrong D, Jabali B, Hanafi M Bioorg Med Chem. 2024; 106:117749.

PMID: 38744018 PMC: 11144469. DOI: 10.1016/j.bmc.2024.117749.